Johnson FM - Search Results

1

Inhibition of c-Src expression and activation in malignant pleural mesothelioma tissues leads to apoptosis, cell cycle arrest, and decreased migration and invasion.

Tsao AS, He D, Saigal B, Liu S, Lee JJ, Bakkannagari S, Ordonez NG, Hong WK, Wistuba I, Johnson FM. Tsao AS, et al. Among authors: johnson fm. Mol Cancer Ther. 2007 Jul;6(7):1962-72. doi: 10.1158/1535-7163.MCT-07-0052. Mol Cancer Ther. 2007. PMID: 17620427

2

Phase I study of weekly alternating therapy with irinotecan/cisplatin and etoposide/cisplatin for patients with small-cell lung cancer.

Johnson FM, Kurie JM, Peeples BO, Lee JJ, Feng L, Pisters KM, Fossella FV, Papadimitrakopoulou VA, Blumenschein GR, Komaki R, Glisson BS. Johnson FM, et al. Clin Lung Cancer. 2003 Jul;5(1):40-5. doi: 10.3816/CLC.2003.n.020. Clin Lung Cancer. 2003. PMID: 14596703 Clinical Trial.

3

Cyclooxygenase-2 induction and prostaglandin E2 accumulation in squamous cell carcinoma as a consequence of epidermal growth factor receptor activation by imatinib mesylate.

Johnson FM, Yang P, Newman RA, Donato NJ. Johnson FM, et al. J Exp Ther Oncol. 2004 Dec;4(4):317-25. J Exp Ther Oncol. 2004. PMID: 15844661

4

Induction of heparin-binding EGF-like growth factor and activation of EGF receptor in imatinib mesylate-treated squamous carcinoma cells.

Johnson FM, Saigal B, Donato NJ. Johnson FM, et al. J Cell Physiol. 2005 Nov;205(2):218-27. doi: 10.1002/jcp.20383. J Cell Physiol. 2005. PMID: 15887238

5

A phase I/II study of neoadjuvant chemotherapy followed by radiation with boost chemotherapy for advanced T-stage nasopharyngeal carcinoma.

Johnson FM, Garden AS, Palmer JL, Shin DM, Morrison W, Papadimitrakopoulou V, Khuri F, Clayman G, Goepfert H, Ang KK, Hong WK, Glisson BS. Johnson FM, et al. Int J Radiat Oncol Biol Phys. 2005 Nov 1;63(3):717-24. doi: 10.1016/j.ijrobp.2005.03.001. Int J Radiat Oncol Biol Phys. 2005. PMID: 16199307 Clinical Trial.

6

Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells.

Johnson FM, Saigal B, Talpaz M, Donato NJ. Johnson FM, et al. Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):6924-32. doi: 10.1158/1078-0432.CCR-05-0757. Clin Cancer Res. 2005. PMID: 16203784

7

Phase I studies of imatinib mesylate combined with cisplatin and irinotecan in patients with small cell lung carcinoma.

Johnson FM, Krug LM, Tran HT, Shoaf S, Prieto VG, Tamboli P, Peeples B, Patel J, Glisson BS. Johnson FM, et al. Cancer. 2006 Jan 15;106(2):366-74. doi: 10.1002/cncr.21640. Cancer. 2006. PMID: 16342249 Free article. Clinical Trial.

8

SRC-family kinases are activated in non-small cell lung cancer and promote the survival of epidermal growth factor receptor-dependent cell lines.

Zhang J, Kalyankrishna S, Wislez M, Thilaganathan N, Saigal B, Wei W, Ma L, Wistuba II, Johnson FM, Kurie JM. Zhang J, et al. Among authors: johnson fm. Am J Pathol. 2007 Jan;170(1):366-76. doi: 10.2353/ajpath.2007.060706. Am J Pathol. 2007. PMID: 17200208 Free PMC article.

9

Abrogation of signal transducer and activator of transcription 3 reactivation after Src kinase inhibition results in synergistic antitumor effects.

Johnson FM, Saigal B, Tran H, Donato NJ. Johnson FM, et al. Clin Cancer Res. 2007 Jul 15;13(14):4233-44. doi: 10.1158/1078-0432.CCR-06-2981. Clin Cancer Res. 2007. PMID: 17634553

10

SRC family nonreceptor tyrosine kinases as molecular targets for cancer therapy.

Johnson FM, Gallick GE. Johnson FM, et al. Anticancer Agents Med Chem. 2007 Nov;7(6):651-9. doi: 10.2174/187152007784111278. Anticancer Agents Med Chem. 2007. PMID: 18045060 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

210 results

Search Page

Filters